# Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy

> **NCT01153932** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 53 (actual)

## Conditions studied

- Muscular Dystrophies

## Interventions

- **DRUG:** GSK2402968
- **DRUG:** matched placebo

## Key facts

- **NCT ID:** NCT01153932
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-03
- **Final completion:** 2012-09
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2014-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01153932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01153932, "Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01153932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*